Using Artificial Intelligence to Improve Clinical Trial Efficiency and Optimization

Craig Morgan
Head of Marketing, Study Startup

The complexity of initiating studies continues to grow, a confluence of complicated protocols, globalization, and regulatory changes, at a time when there is intense pressure to speed clinical trials and restrain costs. Key to reducing these complexities is the ability to be able to leverage operational insights with granular performance metrics and machine learning, which can guide clinical research staff in their daily activities.

Machine learning technologies can help predict outcomes in clinical trials, leading to faster drug approval times, lower costs, and more funding to develop new treatments. More accurate predictions can reduce the uncertainty in study execution by providing greater risk transparency and allowing informed data-driven decisions to be made in the risk assessment and portfolio management of investigational drugs in clinical trials.

How can machine learning deliver business intelligence before starting studies?

Please join us for this webcast:

Live: Tuesday, May 26, 2020

1pm EDT | 12pm CDT | 10am PDT

On Demand: available after airing until May 26, 2021

This webcast will explore:

  • What is required in order to make machine learning a reality?
  • The applicability of machine learning to make more precise predictions in planning studies now
  • How machine learning can be leveraged now to improve daily activities for clinical research staff
  • Where machine learning/artificial intelligence can provide the most value:
    • Impact on study design: traditional site-based trials vs. decentralized trials?
    • Impact on country selection?
    • Impact on KPIs: balancing enrollment vs. speed?

This webcast is applicable to:

  • Sponsor and CRO roles responsible for site identification, feasibility assessment, selection and activation
  • Sponsor and CRO roles responsible for collecting and evaluating trial metrics
  • Sponsor and CRO roles responsible for project management of studies and operational excellence


JEFF KASHER, President, Patients Can't Wait

Jeff Kasher is a known pharmaceutical development change expert with 28 years of experience at Eli Lilly. He is passionate for improving outcomes, bringing patients and research sites into the development process, and dramatically decreasing time to market. His expertise includes novel product development from bench through market launch, research and clinical trial leadership, innovation center start-up as well as new industry paradigm creation.

Jeff is President of Patients Can't Wait; an Independent Director for Javara and Catalyst Clinical Research; and Advisory Board member for Antidote, Be the Partner, BlueCloud, and ZS Associates. He advises several multinational Pharmaceutical companies and CROs. In 2013 CenterWatch Jeff was named one of the “20 Innovators Changing the Face of the Clinical Trials Industry.” He received a B.S. in Chemistry from Franklin & Marshall College, a Ph.D. in Pharmacology from the State University of New York, and a Post-Doctoral Fellowship in Physiology at Yale University School of Medicine.


MOE ALSUMIDAIE, Head of Research, CliniBiz

Moe Alsumidaie is Head of Research at CliniBiz, an Integrated Research Organization focused on advancing therapies through novel technologies and clinical operational workflows. Moe has more than 15 years of extensive experience in clinical operations and computer data science. Moe has worked in clinical project management for institutions including Stanford Medical Center, and The Mount Sinai Medical Center, and Fortune 500 & 100 biopharmaceutical and medical device enterprises including Abbott Vascular Devices, Genentech and Roche. Moe is an Editorial Advisory Board member and columnist at Applied Clinical Trials and speaks regularly at industry conferences. Moe holds a BS in Physiology & Neuroscience from UC San Diego, an MBA and a MS in Investment Finance from Northeastern University’s D’Amore McKim School of Business.

ROB SCOTT, Chief Medical Officer and VP of Development, AbbVie

Dr Rob Scott is Zimbabwean born and a graduate of University of Cape Town. Rob has held leadership positions in global Pharma for over thirty years. At Pfizer he developed Lipitor and Norvasc, including personal involvement in many large-scale CV trials. At AtheroGenics, he designed and implemented the first large cardiovascular outcomes study to be wholly performed by a small biotech. At Amgen, Rob conducted the first outcome study for a PCSK9i, FOURIER. Rob was a member of the FDA Cardiac and Renal Drug Advisory Committee from 2012 to 2016. Rob is currently the Chief Medical Officer at Abbvie with responsibility for around 40 new molecular entities, four thousand people and a budget of close to US$3 billion. He also created the Development Design Center, a Center of Excellence focused on using predictive analytics and big data to design and implementing clinical trials. He is a board member of Transcelerate and a member of the PhRMA R&D Leadership Forum. Rob is a leader in digital transformation of clinical research.

ELVIN THALUND, Director, Industry Strategy, Oracle Health Sciences

Elvin is a recognized industry expert in clinical trials, having over twenty years of experience working as a Clinical Business Analyst Consultant at major pharmaceutical companies including, Hoffmann-La Roche and Johnson & Johnson. Elvin works as a product strategist and system architect in Oracle Health Sciences effort to optimize study startup. Elvin is the co-chair on the TMF Reference Model Exchange Mechanism and holds a Master of Science in Industrial Engineering from Aalborg Universitet.

Be the first to comment

Comments ( 0 )
Please enter your name.Please provide a valid email address.Please enter a comment.CAPTCHA challenge response provided was incorrect. Please try again.